ArticleParasites & vectors2025
Systematic suppression of Leishmania (Leishmania) amazonensis-mediated delayed-type hypersensitivity response in American cutaneous leishmaniasis.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAmerican cutaneous leishmaniasis (ACL) is a protozoan parasitic disease caused by different Leishmania spp. from L. (Leishmania) and L. (Viannia) subgenera. In Brazil, seven Leishmania spp. act as ACL agents. Infection with L. (L.) amazonensis presents a wide clinical-immunopathological spectrum, ranging from localized cutaneous leishmaniasis (LCL), which usually responds well to antimony therapy, to borderline disseminated cutaneous leishmaniasis (BDCL), which may require twice as much LCL-antimony therapy to cure, and, finally, to anergic diffuse cutaneous leishmaniasis (ADCL), which is highly resistant to any chemotherapy. This clinical variability is driven by different degrees of T-cell immunosuppression, which negatively impact delayed-type hypersensitivity (DTH), as assessed by the Montenegro skin test (MST).
methodsGiven MST's role as a T-cell-mediated resistance marker, we used it for diagnosing and monitoring patients with LCL (n = 8) and BDCL (n = 3) due to L. (L.) amazonensis to assess T-cell immunosuppression in these patients. MST was assessed at diagnosis and after treatment, although one patient with LCL refused treatment. The study took place at the Evandro Chagas Institute (Pará, Brazil), with diagnosis confirmed through parasitological assays, MST using L. (V.) braziliensis antigen, indirect fluorescent antibody test (IFAT)-immunoglobulin (Ig)G serology, histopathology, and PCR. Phenotypic and genotypic analyses were used to identify the primary agent.
resultsMST was negative in all patients, both before and after successful treatment. Notably, one patient with LCL who declined treatment also showed no MST reactivity both before and after spontaneous healing. The absence of MST reactivity persisted for up to 1 year postcure in LCL and up to 2 years in BDCL, indicating a sustained lack of MST reactivity regardless of treatment outcome or spontaneous healing.
conclusionsThe lack of MST reactivity pre- and post-treatment in LCL and BDCL challenges the role of DTH as a marker for T-cell-mediated resistance to L. (L.) amazonensis infection. Moreover, the first case of spontaneous LCL cure by L. (L.) amazonensis showed no MST reactivity pre- or post-resolution, raising doubts about the role of DTH in this process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.